Navigation Links
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
Date:10/29/2013

BOSTON, Oct. 29, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced new 12-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients.  Results from the trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco earlier today.

Additionally, the Company will be holding an evening symposium tomorrow, October 30th, starting at 6:30 pm PT. Dr. Gregg Stone, Dr. Ori Ben-Yehuda and Dr. Jose Henriques will lead the symposium and will be joined by a panel of medical experts.

The MGuard utilizes the Company's proprietary MicroNet™ technology, which is a circular knitted mesh that wraps around the stent to protect patients from plaque debris flowing downstream upon deployment.  This advanced technology allows the MGuard to specifically address the unmet need for STEMI patients, and save the life of those who suffer from heart attacks.

The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60-90 minutes post-procedure. ST-segment resolution is historically known to be a strong predictor of mortality. Secondary endpoint clinical outcomes continued to show a lower mortality rate with the MGuard EPS compared to the control (1.0% vs. 3.3%, p=0.092) at 12 months.  These findings are in line with the previously announced 6 month follow-up results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug eluting stents used as a control (0.5% vs. 2.8%, p=0.056).
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
2. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
3. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
4. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
5. MiStent SES demuestra ser único en el entorno clínico
6. MiStent SES erweist sich im klinischen Umfeld als einzigartig
7. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
8. MiStent SES Shown to be Unique in Clinical Setting
9. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
10. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
11. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Dec. 18 Curemark,s Board of Directors,announced today that ... the,company as a senior scientist and will serve on ... of the Department of,Pediatrics at The Long Island College ... New York Health Science Center at Brooklyn., "Dr. ...
... Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... (FDA) has granted Orphan,Drug Designation for IPLEX(TM) for ... currently conducting a 24-week Phase III,enabling trial for ... grant of,approximately $2.1 million from the Muscular Dystrophy ...
Cached Medicine Technology:Curemark Appoints Preeminent Pediatrics Gastroenterologist 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... DC (February 1, 2010) Through the use of ... how to teach their child to communicate and improve ... 2010 issue of The Journal of Positive Behavior ... and SAGE)., Family members play a central role in ...
... blue skies and majestic mountains provided a scenic ... the most promising technologies on the horizonnanomedicine, or ... dedicated to constructing microscopic probes and biomechanical devices. ... academic, government and industry experts from across a ...
... may someday improve prevention efforts , MONDAY, Feb. 1 (HealthDay ... a pregnant mouse leads to changes inside the uterus that ... fetus. , The findings, published online in the ... to prevent and treat premature birth, the study,s senior investigator, ...
... ... you transform the way employees engage inside and outside of the workplace. , ... Milwaukee, Wisc. (PRWEB) February 1, 2010 -- ... the Corporate and Personal Brand,” hosted by Loyola University in Chicago. The hands-on ...
... were more likely to delay having sex, , , MONDAY, ... education classes were more likely to delay having sex, a ... 6th- and 7th-grade students, ranging in age from 10 to ... held on Saturdays at four Philadelphia public schools that draw ...
... and memory skills after 12 weeks of treatment, researchers ... antidepressants after a stroke may help repair the damaged ... , Little has been shown to help the brain ... after initial stroke treatment. But a University of Iowa ...
Cached Medicine News:Health News:Distance education for parents of children with autism found effective 2Health News:Summit examines vast applications of nanomedicine 2Health News:Summit examines vast applications of nanomedicine 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3Health News:Antidepressants After Stroke May Boost Mental Ability 2Health News:Antidepressants After Stroke May Boost Mental Ability 3
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
Medicine Products: